Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;20(8):866-878.
doi: 10.6004/jnccn.2022.0041.

NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022

Thomas W Flaig  1 , Philippe E Spiess  2 , Michael Abern  3 , Neeraj Agarwal  4 , Rick Bangs  5 , Stephen A Boorjian  6 , Mark K Buyyounouski  7 , Kevin Chan  8 , Sam Chang  9 , Terence Friedlander  10 , Richard E Greenberg  11 , Khurshid A Guru  12 , Harry W Herr  13 , Jean Hoffman-Censits  14 , Amar Kishan  15 , Shilajit Kundu  16 , Subodh M Lele  17 , Ronac Mamtani  18 , Vitaly Margulis  19 , Omar Y Mian  20 , Jeff Michalski  21 , Jeffrey S Montgomery  22 , Lakshminarayanan Nandagopal  23 , Lance C Pagliaro  6 , Mamta Parikh  24 , Anthony Patterson  25 , Elizabeth R Plimack  11 , Kamal S Pohar  26 , Mark A Preston  27 , Kyle Richards  28 , Wade J Sexton  2 , Arlene O Siefker-Radtke  29 , Matthew Tollefson  6 , Jonathan Tward  4 , Jonathan L Wright  30 , Mary A Dwyer  31 , Carly J Cassara  31 , Lisa A Gurski  31
Affiliations

NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022

Thomas W Flaig et al. J Natl Compr Canc Netw. 2022 Aug.

Abstract

The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, primary carcinoma of the urethra). These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non-muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Guérin (BCG) shortage; new roles for immune checkpoint inhibitors in non-muscle invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody-drug conjugates for metastatic bladder cancer.

PubMed Disclaimer

MeSH terms

LinkOut - more resources